ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Congressional Committees Add Provisions To Cancer Act Renewal Bills To Strengthen NCI’s Independence, Prevent Fund Withholding

March 8, 1974

In Brief: Deadline June 1 For New ACS Prevention Awards; Money Available To Fund Five More

April 11, 1980

Letter to the Editors: Since 1992, Where Has All The OAM Grant Money Gone?

April 24, 1998

NIh Clinical Center Urged To Create Governing Board

March 15, 1996

Hollings Cancer Center at MUSC Wins NCI Designation

March 6, 2009

FASEB Says NIH Budge Should Reach $10 Bil. In Fiscal 1993

January 10, 1992